beta-alanine has been researched along with 1-(5-isoquinolinesulfonyl)-2-methylpiperazine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baraldi, PG; Borea, PA; Cara, CL; Carrion, MD; Cruz-Lopez, O; Fogli, E; Gessi, S; Moorman, AR; Preti, D; Romagnoli, R; Sacchetto, V; Tabrizi, MA | 1 |
| Colby, KA; Kinoshita, S; Kruse, FE | 1 |
2 other study(ies) available for beta-alanine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
| Article | Year |
|---|---|
From tyrosine to glycine: synthesis and biological activity of potent antagonists of the purinergic P2X7 receptor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine Triphosphate; beta-Alanine; Calcium; Cell Line; Cell Membrane; Cell Membrane Permeability; Ethidium; Fluorescent Dyes; Glycine; Humans; Isoquinolines; Naphthalenes; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2X7; Recombinant Proteins; Structure-Activity Relationship; Sulfonamides; Sulfones; Tyrosine | 2007 |
A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Ophthalmic; Benzoates; beta-Alanine; Clinical Trials as Topic; Fuchs' Endothelial Dystrophy; Humans; Isoquinolines; Ophthalmic Solutions; Protein Kinase Inhibitors; rho-Associated Kinases; Sulfonamides; Treatment Outcome | 2021 |